Monday, 16 June 2025 | 10:30 - 12:30
1.1 Parallel session: Mobilising the research response to Mpox
Presentations:
OA-693 - Strengthening epidemiological, genomic, and community surveillance of mpox virus (MPXV) at the Congo River Border for DRC and RoC
Tania Bishola, University of Kinshasa, Democratic Republic of the Congo
OA-169 - Genomic monitoring and tracking of mpox virus clade Ib after the introduction into Burundi at the end of July until mid-September 2024
Néhémie Nzoyikorera, National Public Health Institute of Burundi, Burundi
OA-747 - Transmission dynamics, clinical outcomes, and pregnancy implications of clade Ib Mpox in South Kivu, Democratic Republic of Congo
Pacifique Ndishimye, Stansile, Canada
OA-306 - Acceptability and perceptions of mpox vaccination and vaccine trials in pregnant women and infants during the PregInPoxVac trial in Boende, Democratic Republic of Congo – ACCEPTED
Marthe Le Prevost, Fondazione Penta ETS, Italy
OA-273 - Strengthening mpox vaccine trials through community engagement: findings from participatory workshops with women, healthcare professionals, and community leaders in Boende, DRC
Marthe Le Prevost, Fondazione Penta ETS, Italy
OA-258 - Closing the evidence gap: advancing maternal mpox vaccination in the DRC – a phase 3 trial on MVA-BN - ACCEPTED
Paulina Morales Ruiz, Global Health Institute, Belgium